- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
35 result(s) found for: pH meter.
Displaying page 1 of 2.
EudraCT Number: 2017-002067-18 | Sponsor Protocol Number: B12CS-B13CS | Start Date*: 2018-12-11 | |||||||||||
Sponsor Name:Advicenne | |||||||||||||
Full Title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses... | |||||||||||||
Medical condition: Cystinuria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002699-26 | Sponsor Protocol Number: PREFECT | Start Date*: 2015-10-08 |
Sponsor Name:GWT-TUD GmbH | ||
Full Title: Pilot study of tolerability and effectivity following application of two combination topical acne products clindamycin 1% and 0.025% tretinoin gel (Acnatac® Gel), adapalen 0,1% and benzoyl peroxide... | ||
Medical condition: acne vulgaris | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-004686-18 | Sponsor Protocol Number: 539 | Start Date*: 2008-02-08 |
Sponsor Name:Bausch&Lomb Dr Gerhard Mann chem.-Fabrik GmbH | ||
Full Title: A multicenter, Investigator-Masked, Parallel Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0.1% Eyedrops Compared with Ketorolac 0.5% Eyedrops in the Ocular Inflammation After... | ||
Medical condition: Prevention of ocular inflammation in adults patients undergoing cataract surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) PT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002068-42 | Sponsor Protocol Number: B14CS | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Advicenne | |||||||||||||
Full Title: Open label, multicentre study, evaluating the safety, tolerability, efficacy, compliance and the acceptability of alkalising treatments at long-term in patients with cystinuria | |||||||||||||
Medical condition: Cystinuria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001647-30 | Sponsor Protocol Number: ESPHALL | Start Date*: 2004-04-28 | |||||||||||
Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA | |||||||||||||
Full Title: An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) | |||||||||||||
Medical condition: Children and adolescents aged 1-17 years at diagnosis, with Ph+ALL | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004808-60 | Sponsor Protocol Number: HD-CAR-1/V04 | Start Date*: 2018-04-12 | ||||||||||||||||
Sponsor Name:University Hospital Heidelberg | ||||||||||||||||||
Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial | ||||||||||||||||||
Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019119-39 | Sponsor Protocol Number: GIMEMALAL1509 | Start Date*: 2011-05-16 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: A multicenter Total Therapy Strategy for De Novo Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients | |||||||||||||
Medical condition: De Novo Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024332-42 | Sponsor Protocol Number: BAY63-2521/13605 | Start Date*: 2014-04-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon... | |||||||||||||
Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000383-18 | Sponsor Protocol Number: LAL1913 | Start Date*: 2014-05-20 |
Sponsor Name:G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto | ||
Full Title: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
Medical condition: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004540-29 | Sponsor Protocol Number: Pona-CELL | Start Date*: 2020-10-06 | |||||||||||
Sponsor Name:Ústav hematologie a krevní transfuze | |||||||||||||
Full Title: Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia | |||||||||||||
Medical condition: NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004942-27 | Sponsor Protocol Number: P16/11 | Start Date*: 2017-07-17 | |||||||||||
Sponsor Name:Centre Hospitalier de Versailles | |||||||||||||
Full Title: A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients with Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: Philadelphia chromosome (Ph)-negative CD22+ B-cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000176-32 | Sponsor Protocol Number: CGX-635-CML-202 | Start Date*: 2006-09-22 |
Sponsor Name:Stragen France | ||
Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (Omacetaxine) (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL G... | ||
Medical condition: Chronic Myeloid Leukaemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001286-15 | Sponsor Protocol Number: CGX-635-CML-203 | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:Stragen France | |||||||||||||
Full Title: A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) who have failed or are intolerant to t... | |||||||||||||
Medical condition: Chronic Myeloid Leukaemia (CML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) FR (Completed) GB (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003337-34 | Sponsor Protocol Number: HZA106853 | Start Date*: 2012-03-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: HZA106853: A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy. | |||||||||||||
Medical condition: Children aged 5-11 years with persistent uncontrolled asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) Outside EU/EEA PL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003225-15 | Sponsor Protocol Number: HALO-ICU | Start Date*: 2017-12-19 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI | |||||||||||||
Full Title: Comparison between inhaled sedation with Sevoflurane vs endovenous sedation with Propofol in the Intensive Care Unit: a randomized prospective trial | |||||||||||||
Medical condition: Preoperative-scheduled sedation in surgical patients admitted in the Intensive Care Unit (ICU) for postoperative monitoring | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003338-15 | Sponsor Protocol Number: HZA106855 | Start Date*: 2012-04-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: HZA106855: A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma. | |||||||||||||
Medical condition: Chronic disease of the lungs characterized by airway inflammation, bronchoconstriction and increased airway responsiveness. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) Outside EU/EEA PL (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018418-53 | Sponsor Protocol Number: CSTI571A2110 | Start Date*: 2010-06-01 | ||||||||||||||||
Sponsor Name:Novartis Pharma Service AG | ||||||||||||||||||
Full Title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia... | ||||||||||||||||||
Medical condition: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) NL (Prematurely Ended) HU (Completed) DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003006-32 | Sponsor Protocol Number: ALL2418 | Start Date*: 2019-07-08 | ||||||||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | ||||||||||||||||||
Full Title: "A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hemato... | ||||||||||||||||||
Medical condition: Acute B-cell Lymphoblastic Leukemia with minimal residual positive disease prior to haematopoietic stem cell transplantation in adult patients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001398-30 | Sponsor Protocol Number: MEDOPP437 | Start Date*: 2023-05-08 |
Sponsor Name:Medica Scientia Innovation Research, S.L. | ||
Full Title: PHASE II STUDY FOR PIK3CA/PTEN-ALTERED ADVANCED METAPLASTIC BREAST CANCER TREATED WITH MEN1611 MONOTHERAPY OR IN COMBINATION WITH ERIBULIN -THE SABINA STUDY- English PHASE II STUDY WITH MEN1611 M... | ||
Medical condition: Hormone Receptor (HR)-known/ Human Epidermial Growth Factor Receptor 2 (HER2)-negative, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha (PIK3CA)/ Phosphatase and Tensin Homolo... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018314-75 | Sponsor Protocol Number: MT103-203 | Start Date*: 2010-08-05 | |||||||||||
Sponsor Name:Amgen Research (Munich) GmbH | |||||||||||||
Full Title: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor... | |||||||||||||
Medical condition: minimal residual disease (MRD) of B-precursor ALL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
